Vancouver, BC – June 8, 2016 – Aspect Biosystems has been named winner of the ‘Most Promising Startup’ Award at the BC Tech Association’s 2016 Technology Impact Awards (TIAs). The TIAs ceremony took place at the Vancouver Convention Centre on June 7, 2016 with over 1,000 attendees celebrating excellence in technology in British Columbia. It was a memorable night for Aspect with most of the team in attendance.

The 2016 ‘Most Promising Startup’ Award was sponsored by the BC Innovation Council (BCIC) and presented by the BC Minister of Technology, Innovation and Citizen’ Services, the Honourable Amrik Virk.

“I can’t tell you what an honour it is to accept this award on behalf of the outstanding team we have at Aspect Biosystems,” said Tamer Mohamed, Co-founder, President, and CEO. “This award is a testament to the business excellence and the scientific innovation that we are committed to at Aspect. Our company is enabling the printing of human tissue on demand and you only achieve that by bringing together some of the brightest minds in biology, engineering, and business and that’s exactly what we are doing at Aspect.”

For more than two decades, the Technology Impact Awards have celebrated the companies, people, and innovation that continue to put BC on the map as an exciting place to grow a tech company. The ‘Most Promising Startup’ Award acknowledges an early-stage technology company that is generating revenue, and demonstrates significant potential, creativity, and promise for the future.

Aspect sends its sincere congratulations to the other winners of the night and to the other three finalists in the ‘Most Promising Startup’ category: InvestX Capital, RESAAS and Visualping. There were about 40 companies nominated in this category.

“Along with the honour of being named 2016 ‘Most Promising Startup’ comes a sense of responsibility to live up to that promise,” said Tamer. “And that is what we intend to do. We are committed to building a flagship company right here in BC that has the real potential to change the face of pharmaceutical and medical research and practice.”